What is Hansoh Pharmaceutical Group Co FCF Yield %?
Hansoh Pharmaceutical Group CoHNSPF 90 FCF Yield % is 3.36 as of Jul. 03, 2026, which is 32% above its 10-year median of 2.54. GuruFocus rates HNSPF with a GF Score™ of 90/100 and a GF Value™ of $3.00 (Modestly Overvalued). Among 1,006 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 67% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Hansoh Pharmaceutical Group Co FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Hansoh Pharmaceutical Group Co FCF Yield % Related Terms
Hansoh Pharmaceutical Group Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co (HNSPF) has a FCF Yield % of 3.36 as of Jul. 03, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 32% above median its historical median of 2.54. Over the past decade, Hansoh Pharmaceutical Group Co's FCF Yield % has ranged from 0.42 to 4.80. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #332 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 33%.
Is Hansoh Pharmaceutical Group Co's FCF Yield % too high?
Hansoh Pharmaceutical Group Co's current FCF Yield % of 3.36 is 32% above median its 10-year median of 2.54. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 4.80. The Drug Manufacturers industry median FCF Yield % is 0.67. Hansoh Pharmaceutical Group Co's value of 3.36 is 405.3% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #332 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #332 out of 1006 companies for FCF Yield %. This puts Hansoh Pharmaceutical Group Co in the upper half of its industry. The industry median FCF Yield % is 0.67. Hansoh Pharmaceutical Group Co's value of 3.36 is 405.3% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own FCF Yield % has ranged from 0.42 to 4.80 over the past decade. While the company's 10-year median is 2.54 vs. the industry median of 0.67, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current FCF Yield % of 3.36 is 405.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current FCF Yield % is 3.36, which is 32% above median its own 10-year median of 2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $3.83 — trading 27.5% above its estimated fair value. The current FCF Yield % is 3.36, which is 32% above median its 10-year median of 2.54 and 405.3% above the Drug Manufacturers industry median of 0.67. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current FCF Yield % is 3.36 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 27.5% above its estimated GF Value™ of $3.00.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
FCF Yield %: 3.36 (32% above median its 10-year median of 2.54)
GF Value™: $3.00 vs. price of $3.83 (27.5% above fair value)
Industry Position: 405.3% above the Drug Manufacturers median (#332 of 1006)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score
Get the complete analysis for HNSPF
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
